Remdesivir can Now Be Bought Directly From the Company
Supply of our investigational COVID-19 treatment is now meeting demand in the U.S. Today, Gilead has assumed responsibility for U.S. distribution of the drug. Read more: https://t.co/MtZVLkL3SH— Gilead Sciences (@GileadSciences) October 1, 2020
Health Editor’s Note: Gilead is able to keep production of remdesivir (veklury) up and is meeting demand for this antiviral in the U.S. Remdesivir is currently authorized for Temporary use under an Emergency Use Authorization (EUA) for treatment of COVID-19 patients in the hospital, moderate to severe disease, regardless of the need for supplemental oxygen.
“Veklury has broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, SARS, Marburg, MERS and SARS-CoV-2, the virus that causes COVID-19. Data from three randomized, controlled clinical trials in hospitalized patients with COVID-19 have consistently demonstrated the clinical benefits of treatment with Veklury. In the placebo-controlled ACTT-1 study, Veklury significantly improved time to recovery and also reduced the likliehood of progression of the disease.”
At this point I am wondering what more this drug needs to do to be considered acceptable treatment for COVID-19? The only potential difficulty I see in the use of remdesivir is that it has to be administered by IV (one dose and then a loading dose daily for up to 10 days) which limits who can administer it. ……Carol